Investor Woodford calls for outsider to head GlaxoSmithKline
Fund manager Neil Woodford, a top investor in GlaxoSmithKline and a critic of the drugmaker's current structure, said on Thursday he wanted to see an outsider replace Andrew Witty as the group&039;s chief executive. "I have a strong preference for an external candidate," Woodford said in an e-mailed statement. Britain&039;s biggest drugmaker said on Thursday that Witty would retire at the end of March 2017, after leading the company since 2008, and the board would consider both internal and external candidates to replace him.
